Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A fixed combination of cinnarizine/dimenhydrinate for the treatment of patients with acute vertigo due to vestibular disorders : a randomized, reference-controlled clinical study

A Hahn, I Sejna, B Stefflova, M Schwarz, W Baumann

. 2008 ; 28 (2) : 89-99.

Language English Country New Zealand

Document type Comparative Study

E-resources Online

NLK ProQuest Central from 2008-06-01 to 1 year ago
Health & Medicine (ProQuest) from 2008-06-01 to 1 year ago

BACKGROUND AND OBJECTIVE: Vestibular dysfunction commonly leads to - often severe - vertigo symptoms. The objective of this study was to compare the antivertiginous efficacy and tolerability of a fixed combination of cinnarizine/dimenhydrinate with those of betahistine in patients with acute vertigo due to vestibular disorders. METHODS: Sixty-six patients experiencing acute vertigo attacks participated in this prospective, double-blind, three-centre, comparative study. Patients who assessed at least one vertigo symptom as being of medium intensity (> or =2) on a 5-point visual analogue scale (VAS; from 0 = no symptoms to 4 = very severe symptoms) were randomly allocated to treatment with the fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg three times daily or betahistine 12 mg three times daily for 4 weeks. The primary efficacy endpoint was change in mean vertigo score, as determined by patients' assessments of 12 individual vertigo symptoms on the 5-point VAS after 4 weeks of treatment. RESULTS: Treatment with the fixed combination led to significantly greater improvements in mean vertigo scores than the reference therapy betahistine after 4 weeks of therapy (p = 0.013). The differences were clinically relevant, based on the Mann-Whitney estimator. Furthermore, the incidence of vertigo-associated vegetative symptoms was significantly reduced after 1 (p = 0.004) and 4 weeks (p = 0.023) in the fixed-combination group relative to the betahistine group. Three patients, all of them in the betahistine group, reported adverse events, none of which was considered serious. Almost all patients (n = 62) rated the tolerabilities of both medications as very good or good. CONCLUSION: The fixed combination of cinnarizine/dimenhydrinate was shown to be an effective and very well tolerated treatment option for patients with acute vertigo due to vestibular disorders. The combination proved to be significantly more efficient in reducing vertigo and associated vegetative symptoms than betahistine in such patients.

000      
03867naa 2200493 a 4500
001      
bmc10034989
003      
CZ-PrNML
005      
20111210200447.0
008      
101221s2008 nz e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a nz
100    1_
$a Hahn, Aleš, $d 1947-2020 $7 nlk19990073180
245    12
$a A fixed combination of cinnarizine/dimenhydrinate for the treatment of patients with acute vertigo due to vestibular disorders : a randomized, reference-controlled clinical study / $c A Hahn, I Sejna, B Stefflova, M Schwarz, W Baumann
314    __
$a Ear, Nose and Throat Department, Faculty Hospital Kralovske Vinohrady (FNKV), 3rd Medical Faculty, Charles University, Prague, Czech Republic.
520    9_
$a BACKGROUND AND OBJECTIVE: Vestibular dysfunction commonly leads to - often severe - vertigo symptoms. The objective of this study was to compare the antivertiginous efficacy and tolerability of a fixed combination of cinnarizine/dimenhydrinate with those of betahistine in patients with acute vertigo due to vestibular disorders. METHODS: Sixty-six patients experiencing acute vertigo attacks participated in this prospective, double-blind, three-centre, comparative study. Patients who assessed at least one vertigo symptom as being of medium intensity (> or =2) on a 5-point visual analogue scale (VAS; from 0 = no symptoms to 4 = very severe symptoms) were randomly allocated to treatment with the fixed combination of cinnarizine 20 mg and dimenhydrinate 40 mg three times daily or betahistine 12 mg three times daily for 4 weeks. The primary efficacy endpoint was change in mean vertigo score, as determined by patients' assessments of 12 individual vertigo symptoms on the 5-point VAS after 4 weeks of treatment. RESULTS: Treatment with the fixed combination led to significantly greater improvements in mean vertigo scores than the reference therapy betahistine after 4 weeks of therapy (p = 0.013). The differences were clinically relevant, based on the Mann-Whitney estimator. Furthermore, the incidence of vertigo-associated vegetative symptoms was significantly reduced after 1 (p = 0.004) and 4 weeks (p = 0.023) in the fixed-combination group relative to the betahistine group. Three patients, all of them in the betahistine group, reported adverse events, none of which was considered serious. Almost all patients (n = 62) rated the tolerabilities of both medications as very good or good. CONCLUSION: The fixed combination of cinnarizine/dimenhydrinate was shown to be an effective and very well tolerated treatment option for patients with acute vertigo due to vestibular disorders. The combination proved to be significantly more efficient in reducing vertigo and associated vegetative symptoms than betahistine in such patients.
650    _2
$a akutní nemoc $7 D000208
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a cinarizin $x chemie $x terapeutické užití $7 D002936
650    _2
$a dimenhydrinát $x chemie $x terapeutické užití $7 D004111
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a fixní kombinace léků $7 D004338
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a periodicita $7 D010507
650    _2
$a tablety $7 D013607
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vertigo $x etiologie $x farmakoterapie $7 D014717
650    _2
$a vestibulární nemoci $x komplikace $7 D015837
650    _2
$a financování organizované $7 D005381
650    _2
$a randomizované kontrolované studie jako téma $7 D016032
655    _2
$a srovnávací studie $7 D003160
700    1_
$a Šejna, Ivan. $7 xx0216530
700    1_
$a Štefflová, Bohdana. $7 xx0246331
700    1_
$a Schwarz, M
700    1_
$a Baumann, W
773    0_
$w MED00001123 $t Clinical drug investigation $g Roč. 28, č. 2 (2008), s. 89-99 $x 1173-2563
910    __
$a ABA008 $b x $y 7
990    __
$a 20110223133337 $b ABA008
991    __
$a 20110414155526 $b ABA008
999    __
$a ok $b bmc $g 823426 $s 688853
BAS    __
$a 3
BMC    __
$a 2008 $b 28 $c 2 $d 89-99 $i 1173-2563 $m Clinical drug investigation $n Clin. drug invest. $x MED00001123
LZP    __
$a 2011-2B/ewme

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...